Claims
- 1. An isolated adipose tissue derived stromal cell has been induced to express at least one characteristic of a neuronal cell.
- 2. An isolated adipose tissue derived stromal cell has been induced to express at least one characteristic of an astroglial cell.
- 3. An isolated adipose tissue derived stromal cell has been induced to express at least one characteristic of a hematopoietic progenitor cell.
- 4. An isolated adipose tissue derived stromal cell that has been induced to express at least one characteristic of a hepatic cell.
- 5. An isolated adipose tissue derived stromal cell that has been dedifferentiated such that it has an absence of phenotypic adipose markers.
- 6. An isolated adipose tissue derived stromal cell has been induced to express at least one characteristic of a neurona, astroglial, or hematopoietic progenitor, or hepatic cell in which at least one non-endogenous nucleic acid sequence has been introduced into the cell.
- 7. A method for treating a neurological disorder in a host comprising administering an isolated adipose tissue derived stromal cell that has been induced to express at least one characteristic of a neuronal cell.
- 8. A method for treating a neurological disorder in a host comprising administering an isolated adipose tissue derived stromal cell that has been induced to express at least one characteristic of an astroglial cell.
- 9. A method of improving hepatic function in a patient, comprising administering adipose tissue derived stromal cells induced to express at least one characteristic of a hepatic cell into the hepatic system of a patient.
- 10. A method of improving hematopoietic function in a patient, comprising administering adipose tissue derived stromal cells induced to express at least one characteristic of a hematopoietic progenitor cell into the hematopoietic system of a patient.
- 11. A method for dedifferentiating isolated adipose tissue-derived stromal cells comprising: plating said isolated adipose tissue-derived stromal cells and incubating said cells in medium comprising serum and an embryonic extract.
- 12. A method for dedifferentiating isolated adipose tissue-derived stromal cells, comprising: plating said isolated adipose tissue-derived stromal cells at a density of approximately 1,000 to 500,000 cells/cm2 and incubating said cells in medium comprising i) serum; ii) at least one compound selected from the group consisting of: growth factors, hormones, cytokines and serum factors; and iii) optionally, an embryonic extract.
- 13. A method for inducing an isolated adipose tissue-derived stromal cell to differentiate into a cell of non-mesenchymal lineage, comprising: plating said isolated adipose tissue-derived stromal cells and incubating said cells in medium comprising i) serum; ii) at least one compound selected from the group consisting of: growth factors, hormones, cytokines and serum factors; and iii) an embryonic extract.
- 14. The method of claim 7, 8, or 9, wherein said adipose-derived stromal cells are human.
- 15. The method of claim 7, 8, or 9, wherein said adipose tissue-derived stromal cells are isolated from omental adipose tissue.
- 16. The method of claim 7, 8, or 9, wherein said serum is fetal calf serum.
- 17. The method of claim 12, wherein said fetal calf serum is present in said medium at a concentration of about 1 to 30 percent.
- 18. The method of claim 13, wherein said fetal calf serum is present in a said medium at a concentration of about 3 to 10 percent.
- 19. The method of claim 7, 8, or 9, wherein said medium contains about 1 to 30% embryonic extract of chicken.
- 20. The method of claim 15, wherein said concentration of embryonic extract of chicken is about 5 to 15 percent.
- 21. The method of claim 7 or 8, wherein said growth factor is selected from the group consisting of: EGF, aFGF, bFGF, NGF, BDNF, bone morphogenetic proteins, ciliary neurotrophic factor, PDGF, HBGF, IGF-I, IGF-II, TGF-α, TGF-β, IL-2, IL-3, IL-7, erythropoietin, c-kit ligand/stem cell factor, and midkine.
- 22. The method of claim 7 or 8, wherein said hormone is selected from the group consisting of: growth hormone, insulin and insulin like growth factors.
- 23. The method of claim 9, wherein said cell of non-mesenchymal lineage is selected from the group consisting of hematopoietic cells and neuronal cells.
- 24. The method of claim 9, further comprising the step of introducing said plated cells into a mammalian subject.
- 25. The method of claim 20, wherein said adipose-derived stromal cells are isolated from said subject.
- 26. A pleuripotent stem cell produced by the method of claim 7 or 8.
- 27. A hematopoietic cell produced according to the method of claim 19 or 20.
- 28. A neuronal cell produced according to the method of claim 19 or 20.
- 29. A pleuripotent stem cell generated from isolated adipose tissue-derived stromal cells.
- 30. A method for providing differentiated cells of a non-mesenchymal lineage to a subject, comprising:
a) plating said isolated adipose tissue-derived stromal cells at a density of 1,000 to 500,000 cells/cm2 and incubating said cells in medium comprising serum and an embryonic extract; b) introducing the cells from step (a) into said subject; wherein cells of the desired type are typically present at corresponding site in a normal subject.
- 31. The method of claim 26, wherein said site is CNS tissue and said differentiated cell type is neuronal.
- 32. The method of claim 27, wherein said cell type is astroglial.
- 33. The method of claim 26, wherein said site is intravenous and said differentiated cell type is hematopoietic.
- 34. The method of claim 26, wherein said subject is mammalian.
- 35. The method of claim 30, wherein said subject is human.
- 36. A method of improving hematopoiesis in a patient, comprising administering cells of claim 17 into said patient.
- 37. The method of claim 32, wherein said transplantation is by intravenous infusion.
- 38. The cell of claim 22, wherein said cell is transiently or stably transfected with at least one nucleic acid sequence.
- 39. The cell of claim 22, wherein said cell is infected with a viral or other vehicle containing at least one desired nucleic acid sequence to be introduced into said cell.
- 40. A dedifferentiated, isolated, adipose tissue derived stromal cell capable of being induced to express at least one characteristic of a non-adipose tissue derived cell.
- 41. An isolated adipose tissue derived stromal cell has been induced to express at least one characteristic of a neuronal cell.
- 42. A composition that includes an adipose tissue derived stromal cell has been induced to express at least one characteristic of an astroglial cell in combination with a pharmaceutically acceptable carrier.
- 43. A composition that includes an adipose tissue derived stromal cell has been induced to express at least one characteristic of a hematopoietic progenitor in combination with a pharmaceutically acceptable carrier.
- 44. A composition that includes an adipose tissue derived stromal cell has been induced to express at least one characteristic of a neuronal, astroglial, hematopoietic, or hepatic derived cell wherein at least one non-endogenous nucleic acid sequence has been introduced into the stromal cell, in combination with a pharmaceutically acceptable carrier.
- 45. An isolated adipose tissue derived stromal cell has been induced to express at least one characteristic of a neuronal cell in a two or three dimensional framework suitable for implantation into a host
- 46. An isolated adipose tissue derived stromal cell has been induced to express at least one characteristic of an astroglial cell in a two or three dimensional framework suitable for implantation into a host.
- 47. An isolated adipose tissue derived stromal cell has been induced to express at least one characteristic of a hematopoietic progenitor cell in a two or three dimensional framework suitable for implantation into a host.
- 48. An isolated adipose tissue derived stromal cell that has been induced to express at least one characteristic of a hepatic cell in a two or three dimensional framework suitable for implantation into a host.
PRIOR APPLICATION
[0001] This application claims priority to U.S. Ser. No. 60/185,338, filed on Feb. 26, 2000.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60185338 |
Feb 2000 |
US |